|
March
20, 2007--GlaxoSmithKline
(GSK) has invested $13 million in a new laboratory in
Singapore. The laboratory opened Tuesday and is part of
GSK’s Center for Research in Cognitive and
Neurodegenerative Disorders, which focuses on finding
treatments for Alzheimer’s disease and schizophrenia.
GSK invested an initial $40 million in the Singapore
center when it opened two years ago. AP/Forbes.com |
